Skip to main content
. 2023 Jan 21;15:17588359221146137. doi: 10.1177/17588359221146137

Figure 4.

Figure 4.

Absolute (pooled) rates for grade ⩾3 AEs for FTD/TPI + BEV and FTD/TPI monotherapy. (a) FTD/TPI + BEV: Grade ⩾3 neutropenia. (b) FTD/TPI monotherapy: Grade ⩾3 neutropenia. (c) FTD/TPI + BEV: Grade ⩾3 febrile neutropenia. (d) FTD/TPl monotherapy: Grade ⩾3 febrile neutropenia. (e) FTD/TPI + BEV: Grade ⩾3 asthenia/fatigue. (f). FTD/TPI monotherapy: Grade ⩾3 asthenia/fatigue. (g) FTD/TPI + BEV: Grade ⩾3 diarrhea. (h) FTD/TPI monotherapy: Grade ⩾3 diarrhea. (i) FTD/TPI + BEV: Grade ⩾3 nausea. (j) FTD/TPI monotherapy: Grade ⩾3 nausea. (k) FTD/TPI + BEV: Grade ⩾3 vomiting. (l) FTD/TPI monotherapy: Grade ⩾3 vomiting.

AEs, adverse events; CI, confidence interval; FE, fixed effects; FTD/TPI, trifluridine/tipiracil; FTD/TPI + BEV, trifluridine/tipiracil + bevacizumab; RE, random effects.